The use of radiotherapy (RT) in the management of leukemia has evolved. Historically, RT was critical for disease control in sanctuary sites, such as the central nervous system (CNS) and testes.

Liquid biopsy technologies, particularly circulating tumor DNA (ctDNA), are an emerging tool in precision oncology with growing relevance in radiation oncology.

This activity focuses on new and emerging indications for radiation in patients with metastatic cancers.

Managing symptoms induced by radiotherapy is an important component of radiation oncology practice.

For the practical radiation oncology program, this activity includes three speakers for education on the following complex presentations for managing advanced stage gynecologic cancer patients.

This activity involves three discussants using case-based presentations to review challenging areas of breast cancer management. The first discussant examines the options for treating patients with recurrent breast cancer.

The activity gives an overview of irradiation of benign diseases. The worldwide unique evidence-based S2-guideline of the German Society for Radiation Oncology (DEGRO) that has been translated into English is also presented.

Although radiotherapy is a well-established treatment modality for both solid and liquid tumors, its utility in the management of benign diseases remains poorly elucidated. In general, oncologists and non-oncologic specialists in the U.S.